Skip to content

The Impact of Daily Carbohydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System

The Impact of Daily CarboHydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System (Medtronic MiniMed 780G): a Multi-center Real-world Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05866900
Acronym
CHOco-AID
Enrollment
347
Registered
2023-05-19
Start date
2023-05-15
Completion date
2023-10-31
Last updated
2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Keywords

MiniMed 780G, automated insulin delivery, nutrition, diet, time in range, insulin pump

Brief summary

Lifestyle factors, including diet, play an important role in the achievement of glycemic targets in patients with diabetes, even with the use of automated insulin delivery (AID) systems. Advanced hybrid closed-loop systems (AHCL), by implementing innovative and powerful control algorithms, have been shown to improve the post-meal glycemic control in their users through the delivery of automatic correction boluses. However, data about the influence of the daily amount of carbohydrate intake on glycemic outcomes in youth with type 1 diabetes using AHCL are missing. Therefore, this study will evaluate the association between daily carbohydrate intakes and meal patterns on glycemic control of young people living with type 1 diabetes using an AHCL system (Medtronic MiniMed 780G; Medtronic, Northridge, California) under real-life conditions.

Interventions

DEVICEMiniMed 780G with SmartGuard activated

The MiniMed 780G system consists of a MiniMed 780G Insulin Pump connected to Guardian 4 Sensor or Guardian 3 Sensor, using an automated insulin delivery algorithm called SmartGuard.

Sponsors

University of Ljubljana, Faculty of Medicine
Lead SponsorOTHER
University of Messina
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
7 Years to 18 Years

Inclusion criteria

* Patients with type 1 diabetes * Patients aged 7-18 years * Patients using Medtronic MiniMed 780G with SmartGuard activated * Patients whose informed consent has been obtained * \>70% CGM data during observational period

Exclusion criteria

* Patients with partial clinical remission according to the Hvidovre Study Group definition * Concomitant treatment with steroids or other drugs known to interfere with blood glucose levels * Previous diagnosis of psychological or eating disorders

Design outcomes

Primary

MeasureTime frameDescription
Time in range (%)6 monthsTime spent with sensor glucose between 70 and 180 mg/dl (3.9 and 10 mmol/L)
Time above range level 1 (%)6 monthsTime spent with sensor glucose between 180 and 250 mg/dl (10.1 and 13.9 mmol/L)
Time above range level 2 (%)6 monthsTime spent with sensor glucose \> 250 mg/dl (13.9 mmol/L)
Time below range level 1 (%)6 monthsTime spent with sensor glucose between 54 and 70 mg/dl (3.0 and 3.8 mmol/L)
Time below range level 2 (%)6 monthsTime spent with sensor glucose \< 54 mg/dl (3.0 mmol/L)
Mean sensor glucose (mg/dl or mmol/L)6 months
Coefficient of variation (%)6 months

Secondary

MeasureTime frame
BMI Z-scoreBaseline, 3 months, 6 months
Weight Z-scoreBaseline, 3 months, 6 months
Height Z-scoreBaseline, 3 months, 6 months

Countries

Italy, Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026